Related Experiment Videos
Novel CCR1 antagonists with improved metabolic stability
Matthew F Brown1, Mike Avery, William H Brissette
1Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. matthew_f_brown@groton.pfizer.com
Bioorganic & Medicinal Chemistry Letters
|April 15, 2004
Summary
Novel CCR1 antagonists were synthesized and evaluated for biological activity and pharmacokinetic properties. These compounds show potential for therapeutic applications by targeting chemokine receptor 1.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Immunology
Background:
- Chemokine receptor 1 (CCR1) is implicated in inflammatory diseases.
- Developing targeted therapies for CCR1-mediated conditions is a significant area of research.
Purpose of the Study:
- To synthesize novel compounds targeting CCR1.
- To evaluate the biological activity and pharmacokinetic profiles of these novel antagonists.
Main Methods:
- Chemical synthesis of novel CCR1 antagonists.
- In vitro assays to assess biological activity.
- In vivo studies to determine pharmacokinetic parameters.
Main Results:
- Successful synthesis of a new series of CCR1 antagonists.
- Demonstrated significant biological activity in relevant assays.
- Characterized favorable pharmacokinetic profiles, indicating potential for drug development.
Conclusions:
- The novel CCR1 antagonists possess promising biological activity and suitable pharmacokinetic properties.
- These compounds represent potential therapeutic candidates for inflammatory diseases mediated by CCR1.